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Responsiveness to the vasopressor, vasodepressor and
chronotropic effects of several sympathomimetic amines
was assessed in 12 patients with severe autonomic dys-
function and in 8 age-matched control subjects. The pa-
tients with autonomic dysfunction showed a profound
increase in responsiveness to both isoproterenol and
phenylephrine as compared with control subjects. The
mean bolus dose of isoproterenol required to increase
heart rate by 25 beats/min was 0.9 + 0.2 p,g in the
patients and 5.4 + 2.1 p,g in the control subjects. The
dose of isoproterenol required to reduce mean blood
Autonomic dysfunction is a debilitating syndrome which is
characterized by severe orthostatic hypotension, anhidrosis,
impotence and usually an attenuated orthostatic tachycardia.
It often occurs secondary to other diseases such as diabetes
mellitus, amyloidosis or malignancy. However, autonomic
dysfunction may also occur as a primary neurologic dis-
order. Patients in this latter category may be subdivided into
those in whom abnormalities seem confined to the auto-
nomic nervous system (idiopathic orthostatic hypotension
or Bradbury-Eggleston syndrome) (I), and those in whom
From the Departments of Medicine and Pharmacology, Vanderbilt Uni-
versity, Nashville, Tennessee. This study was supported in part by U.S.
Public Health Service Research Grants GM 15431, HL 14192 by the
Tennessee Affiliate of the American Heart Association, and by the Hrafn
Sveinbjamarson Foundation, Nashville, Tennessee. Dr. Robertson is the
recipient of a Research Career Development Award from the National
Institutes of Health, Bethesda, Maryland. Dr. Goldberg and Dr. Hollister
are Clinical Associate Physicians in the Elliot V. Newman Clinical Re-
search Center, Nashville, Tennessee. Dr. Rose Marie Robertson is an
Established Investigator of the American Heart Association. This work
was presented at the American Heart Association Meeting in Dallas, Texas,
November 1982. Manuscript received July II, 1983; revised manuscript
received September 26, 1983, accepted September 30, 1983.
Address for reprints: David Robertson, MD, Division of Clinical Phar-
macology, Vanderbilt University, Nashville, Tennessee 37232.
©1984 by the American College of Cardiology
pressure by 25 mm Hg was 0.3 + 0.2 and 5.2 + 1.8
p,g, respectively.
Thus, although there is a 6-fold increase in respon-
siveness to the chronotropic effect of isoproterenol in
autonomic dysfunction, the responsiveness to the drug's
depressor effect is increased 17-fold. This enhanced de-
pressor sensitivity is quite marked, even with oral beta-
adrenoceptor agonists. Beta-adrenoceptor agonists must
be used with caution in conditions associated with auto-
nomic dysfunction if dangerous hypotension is to be
avoided.
other neurologic abnormalities accompany the autonomic
dysfunction (multiple system atrophy or Shy-Drager syn-
drome) (2), Patients with the Bradbury-Eggleston syndrome
generally have a more benign prognosis, but their condition
is often complicated by supine hypertension, Plasma nor-
epinephrine levels in severely affected individuals are often
less than 50 pg/ml and sometimes less than 25 pg/mL The
latter is less than 10% of normal, Patients with the Shy-
Drager syndrome usually have somewhat higher plasma nor-
epinephrine levels (3).
Patients with autonomic dysfunction have an increased
responsiveness to vasoactive substances and stimuli. For
example, mydriatic doses of ophthalmically-applied phen-
ylephrine can lead to marked hypertension in some patients
(4). Excessive hypertensive responses have been seen with
both norepinephrine (5) and angiotensin (6), Finally, such
mild vasodepressor stimuli as food ingestion (7) and hy-
perventilation (8) may significantly lower blood pressure in
these subjects.
We investigated beta-adrenoceptor responsiveness in a
group of patients with the Bradbury-Eggleston syndrome,
Previous investigators (9) have documented a gradual re-
duction in beta-adrenoceptor responsiveness with increasing
age in normal subjects, but the extent to which this might
occur in patients with autonomic dysfunction has not, to our
knowledge, been rigorously assessed.
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Methods
Study subjects. Twelve patients exhibiting clinical fea-
tures consistent with the Bradbury-Eggleston syndrome were
recruited from the Autonomic Dysfunction Clinic of Van-
derbilt University Hospital. There were six men and six
women (Table 1), ranging in age from 54 to 70 years, At
the time of study, all subjects had been receiving no med-
ications for 7 days. The minimal duration of autonomic
dysfunction was 2 years. None had nonautonomic neuro-
logic signs or symptoms or evidence of a secondary cause
of their autonomic dysfunction.
Twelve age-matched. paid, normal volunteers also
underwent study. There were eight men and four women
ranging in age from 54 to 71 years. They had been receiving
no medications for at least 3 weeks,
Protocol. This investigation was approved by the Van-
derbilt Committee for the Protection of Human Subjects.
Informed consent was obtained from each study participant.
All study subjects were admitted to the Elliot V. Newman
Clinical Research Center and placed on a diet containing
150 mEq sodium and 80 mEq potassium. After at least 3
days' equilibration on this diet and when daily urinary so-
dium levels had reached the 125 to 175 mEq range, sen-
sitivity to phenylephrine, isoproterenol, tyramine and var-
ious physiologic stimuli was studied.
Instruments. On the day of study, subjects were kept flat
in bed and took no food or drink after midnight. At 8:00
a.m., an intravenous line with 5% dextrose in water was
begun and run only at a sufficient rate to maintain the line
for use in drug infusion. Immediately afterward, a 21 gauge
butterfly needle was introduced into the radial artery of the
nondominant arm and connected with a Hewlett-Packard
transducer to a Hewlett-Packard four channel recorder. In
some subjects, a 20 gauge Teflon catheter was introduced
using the Seldinger technique and pressure was monitored
as described. Electrocardiographic leads were placed so as
to obtain a tracing in which the QRS magnitude was suf-
ficient to trigger a tachometer. The electrocardiographic in-
put was also processed through a tachometer that plotted
beat to beat heart rate on a vertical axis.
Pharmacologic and physiologic testing. These studies
were carried out in a standardized manner (10). Phenyle-
phrine was administered beginning with a 12.5 J-Lg intra-
venous bolus and continuing at 10 minute intervals with
progressive dosage doubling until an increase in mean blood
pressure of greater than 25 mm Hg was attained. Isopro-
terenol was administered in a similar manner, beginning
with a O. I J-Lg dose and continuing at 10 minute intervals
with dosage doubling until a heart rate increase of greater
than 25 beats/min was obtained. Tyramine was administered
similarly, beginning with 250 J-Lg and continuing until a
mean blood pressure increment of 25 mm Hg or greater was
achieved. In the case of tyramine, a 15 minute interval was
allowed between each administration to permit ample time
for recovery to the baseline state. The responses of blood
pressure and heart rate to the cold pressor test and the Val-
salva maneuver were also assessed.
Responses to upright posture. At another time when the
arterial and venous lines were not in place, the responses
of blood pressure and heart rate to upright posture were
measured. In the subjects with autonomic dysfunction,
standing time was also assessed. In these patients, standing
time is defined as the period of time an individual can stand
motionless before the herald symptom (usually dizziness or
dimming of vision) of reduced cerebral perfusion occurs
(II). In our experience, this has been a more constant in-
dicator of ambulatory functional capacity than the upright
blood pressure in individuals unable to stand as long as 5
minutes.
Catecholamine determinations. In some of the subjects
with autonomic dysfunction, biochemical characterization
of their disease by plasma or urinary catecholamines and
Table 1. Characteristics of Patients With Bradbury-Eggleston Syndrome
Age (yr)
Blood Pressure (mm Hg)
Standing Time
Case & Sex Supine Upright* (seconds)
I 68F 174/94 72/40 IS
2 72M 2101110 70/40 <15
3 58M 167/98 74/64 30
4 59M 158/92 68/60 25
5 61F 1641102 70/60 15
6 61F 184/98 88170 15
7 64M 1501100 60/50 15
8 54M 134/85 60/50 15
9 70M 1661105 84/64 25
IO 68F 190/100 76/62 15
II 70F 2041102 66/56 20
12 68F 152/88 86/66 40
Anhidrosis
+
+
+
+
+
+
+
+
+
+
*Because of the brief time that patients were able to remain upright. this determination is less accurate than that of the supine pressure. F = female;
M = male; + = present; - = absent.
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Table 2. Biochemical and Cardiovascular Findings in the
Patients With the Bradbury-Eggleston Syndrome and in Normal
Subjects
Plasma Urinary Orthostatic Cold Pressor
(pg/ml) (JLgI24h) Response Response
Normal subjects 368 ± 24 41 ± 16 - 4.2 + 24 ± 7
Patients 28 ± 3t 6 ± It - 59.8t - 2 ± 4t
*Data based on Patients 5 to 12 (Patients I to 4 were studied before
the measurement technique became available). tp < 0.001 comparing
normal subjects and patients. The orthostatic response is the change in
mean arterial pressure (AMAP), as determined by sphygmomanometer, on
rising from the supine to the upright posture. The cold pressor response
is the change, as determined by intraarterial measurement, when the right
hand is placed in a bucket of half ice and half water for 60 seconds.
their metabolites was carried out (Table 2). Plasma nor-
epinephrine and epinephrine were measured using a mod-
ification of the radioenzymatic technique of Passon and Peu-
ler (12). Urinary normetanephrine and metanephrine were
measured using a gas chromatography-mass spectrometry
method previously described (13).
the subjects with autonomic dysfunction in whom there ap-
peared to be a tendency to vasodepression in response to
this stimulus.
The results of pharmacologic testing in a 64 year old
patient with the Bradbury-Eggleston syndrome are shown
in Figure I. The linear interpolation method by which stand-
ardization of sensitivity was carried out is clarified in this
figure. It can be seen that 27 J.tg of phenylephrine would
be sufficient to increase mean blood pressure by 25 mm Hg
and that 5,400 J.tg of tyramine is required to achieve the
same increase. An isoproterenol dose of 0.28 J.tg lowered
mean blood pressure by 25 mm Hg while lO-fold higher
concentrations of the drug were required to increase heart
rate by 25 beats/min.
Blood pressure and heart rate tracings from Patient 2
are shown in Figure 2. The responses to two bolus injections
of isoproterenol are shown. It is noteworthy that the 0.5 J.tg
isoproterenol dose that lowered blood pressure by 35120 mm
Hg did not alter heart rate. However, with a subsequent
doubling of isoproterenol dose, a modest increase in heart
rate can be seen to accompany the greater depressor re-
sponse. In contrast to the result in normal subjects, the late
increase in systolic pressure that occurred after the initial
depressor response to isoproterenol was almost entirely ab-
sent in the patients with autonomic dysfunction.
Pharmacologic testing (Fig. 3). In the 12 normal sub-
jects, the mean dose of phenylephrine required to increase
mean blood pressure by 25 mm Hg was 204 ± 28 J.tg; for
patients with autonomic dysfunction, the corresponding dose
was only 42 ± 10 J.tg, indicating a five-fold shift.
For the chronotropic response to isoproterenol. the mean
dose required to increase heart rate by 25 beats/min was 5.4
± 2.1 /-tg in the normal subjects and 0.9 ± 0.2 /-tg in the
patients with autonomic dysfunction. The onset of isopro-
terenol's effect was within 30 seconds in both patients and
control subjects, with no significant difference between these
two groups in rapidity of onset; the patient group did, how-
ever, have a more prolonged depressor response. The dose
of isoproterenol that lowered mean blood pressure by 25
mm Hg was 5.2 ± 1.8 J.tg in the normal subjects but only
0.3 ± 0.2 J.tg in the patients. Although the chronotropic
effect exhibited a 6-fold shift, the depressor effect of iso-
proterenol was 17-fold shifted to the left in the subjects with
the Bradbury-Eggleston syndrome.
Although the doses required to reduce blood pressure by
25 mm Hg and increase heart rate by 25 beats/min were
similar in the normal subjects, the patients with autonomic
dysfunction were approximately three-fold more sensitive
to the depressor than to the chronotropic effect of isopro-
terenol. In fact, it was this greater increase in vascular as
compared with cardiac effect that accounted for the greater
shift in the dose required to achieve these blood pressure
and heart rate goals in the patients compared with the normal
subjects.
AMAP (mm Hg)Norepinephrine*
Results
Clinical characteristics (Table 1). The clinical char-
acteristics of the 12 patients with the Bradbury-Eggleston
syndrome are shown in Table I. None of the patients had
evidence of nonautonomic neurologic involvement in the
anamnesis, the physical examination or the laboratory test-
ing. The impairment in ambulatory function was consid-
erable in all, as evidenced by the brief standing time ca-
pacities they exhibited. All male patients were impotent and
all patients exhibited the usual day-night reversal in urinary
volume. All but one patient had supine hypertension.
The biochemical, orthostatic and cold pressor responses
in the patients with autonomic dysfunction are shown in
Table 2 and compared with the values of normal subjects
we had previously studied. It is clear that the patients with
the Bradbury-Eggleston syndrome had a marked reduction
in supine plasma norepinephrine levels; they were, in fact,
hardly more than 10% of normal. The disparity in urinary
norepinephrine levels is only slightly less remarkable. In
four of the patients and in eight normal subjects, urinary
normetanephrine and metanephrine were measured. The re-
spective values were 280 ± 34 and 120 ± 15 J.tg/day in
the normal subjects and 69 ± 16 (p = 0.05) and 54 ± 18
J.tg/day in the patients. In the other eight patients and four
normal subjects, these variables were not measured. The
profound decrease in blood pressure on assumption of up-
right posture is clearly illustrated in Table 2. Furthermore,
although normal subjects had an increase in mean arterial
pressure during the cold pressor test, this did not occur in
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Figure 1. Case 7. Pharmacologic testing in this 64 year old man
with the Bradbury-Eggleston syndrome. The stepwise manner in
which bolus injections of phenylephrine, isoproterenol and tyra-
mine are given can be seen. Note that although the semilog plots
of phenylephrine and isoproterenol against the variables tested are
linear over the doses used, that of tyramine is usually curved. It
is recognized that the chronotropic and vascular effects of isopro-
terenol do not derive exclusively from effects on the beta,- and
betaz-receptors, respectively, Note that the points under betaz-
receptors represent a decrease rather than an increase in blood
pressure. + BP25 , - BP25 , indicate increase and decrease, re-
spectively, of blood pressure by 25 mm Hg. LlMAP = change in
mean arterial pressure; HR = heart rate; +HR25 = increase in
heart rate of 25 beats/min.
The response ofPatient 2 to an orally administered beta-
adrenoceptor agonist is shown in Figure 4. Because a re-
view of reported data (14,15) suggested that terbutaline at
an oral dosage of 5 mg would produce a small increase in
systolic pressure, a small decrease in diastolic pressure and
a 3 to 5 beat/min increase in heart rate, we selected a dose
half this size for our study. In response to this modest 2.5
mg dose of terbutaline, the patient had a sustained 30 to 40
mm Hg decrease in systolic blood pressure and a 10 to 15
mm Hg decrease in diastolic pressure. Heart rate increased
dramatically.
Discussion
Hyperresponsiveness to pressor and depressor stimuli is
a well established feature of autonomic dysfunction. Ex-
cessive hypertension has been seen with small doses of
norepinephrine (5), angiotensin II (6), phenylephrine (4)
~ -BP(mm Hg)
HR
( bpm)
200
150
100
50
o
100
50
o
t
ISO
0.5)19
t
ISO
1.0)19
Figure 2. Case 2. Blood pressure (BP) and heart rate (HR)
response to isoproterenol (ISO) in this patient with the
Bradbury-Eggleston syndrome. These tracings show the
blood pressure (BP) (upper panels) and heart rate re-
sponses (lower panels) after two doses of isoproterenol,
illustrating the early appearance of the vasodepression and
the comparatively late appearance of the heart rate re-
sponse. Each tracing represents a time frame of 5 minutes.
ISO = isoproterenol bolus given intravenously,
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Figure 3. Hypersensitivity to alpha- (al) and beta- (f31 and f3z)
adrenoreceptor agonists in autonomic dysfunction, Doses of the
agents (mean values ± standard deviation) required to achieve the
blood pressure (BP) and heart rate (HR) goals are shown on the
left. The patient sensitivity as a function of normal sensitivity is
displayed as fold shift on the right. All differences between normal
subjects (C) and patients witl! the Bradbury-Eggleston syndrome
were very highly significant. X = mean; SD = standard deviation;
other abbreviations as before.
and vasopressin (16). Excessive hypotension has been ob-
served with nitrates (8,17) and anesthesia (18). Because
reduced sensitivity to isoproterenol has been found with
increasing age, we investigated the sensitivity of patients
with autonomic dysfunction to this agent, in terms of in-
creasing heart rate and decreasing blood pressure.
Previous studies on beta-receptor function in patients
with autonomic dysfunction. In 1966, Burckhardt and
Strassle (19) reported that intravenous propranolol at 60
J.Lg/min increased blood pressure slightly but that oral pro-
pranolol, 10 mg three times daily, worsened blood pressure
in a 63 year old man with probable Bradbury-Eggleston
syndrome. In 1974, Miller et al. (20) reported that a 53 year
old woman with orthostatic hypotension and orthostatic
tachycardia of unknown cause had an approximately 25 mm
Hg increase in blood pressure when propranolol, 10 mg four
times daily, was given. In 1975, Anlauf et al. (21) reported
careful studies in three patients with autonomic dysfunction.
In each case, a depressor effect of isoproterenol was ob-
served. Metaproterenol, 120 mg, significantly lowered di-
astolic blood pressure and almost doubled heart rate (21).
Sensitivity (X ± S,D,) Pindolol, 15 mg daily, seemed to increase blood pressure
(21 ).
In 1977, Chobanian et al. (22) systematically investigated
the effect of propranolol in five well characterized patients
with severe orthostatic hypotension and low plasma cate-
cholamines. They found that four of five had a pressor
response to intravenous propranolol in doses ranging from
1 to 5 mg. Interestingly, although the beta-receptor blocking
effects of the drug would be expected to be immediately
manifest, the maximal increases in blood pressure occurred
as long as 90 minutes after drug administration. Oral therapy
with 40 to 240 mg daily was efficacious in four subjects;
one subject had to be withdrawn after I week of therapy
because of excessive hypertension on 40 mg daily. Cho-
banian et al. suggested that propranolol might be useful in
the management of occasional patients with severe auto-
nomic dysfunction.
A number of investigators have subsequently observed
benefit from either pure beta-antagonists (23,24) or antag-
onists possessing intrinsic sympathomimetic activity (25-29).
The mechanism by which these agents benefit patients with
autonomic dysfunction has not been adequately explained.
Present study. Our investigation was carried out to as-
sess the relative functional hypersensitivity in response to
both alpha and beta stimuli. Both direct- and indirect-acting
agents were employed. Phenylephrine was selected to assess
alpha,-receptor function because this agent has little effect
on other receptor subtypes at clinically employed doses.
Isoproterenol was used to determine sensitivity to beta stim-
uli. This agent is known to act powerfully on both betal'
and betarreceptors. Tyramine was used to test neuronal
stores of norepinephrine. Insensitivity to tyramine suggests
reduced neuronal stores of norepinephrine, reduced norad-
renergic neuron numbers or reduced alpha-adrenoceptor
function. When phenylephrine sensitivity confirms intact
alpha-adrenoceptors, the latter possibility is no longer
applicable.
The patients with the Bradbury-Eggleston syndrome
demonstrated comparable hypersensitivity to the pressor ef-
fect of phenylephrine and the chronotropic effect of isopro-
terenol. In each case, an approximately six-fold shift to the
left in the dose-response curve was found. In marked con-
trast, the dose-response curve of the depressor response to
isoproterenol was shifted 17-fold to the left. This disparity
between predominant beta, and predominant betaz respon-
siveness occurred in all 12 patients studied. We have also
seen it in patients with the Shy-Drager syndrome.
The mechanism of increased beta-adrenoceptor reo
sponsiveness in patients with autonomic dysfunction.
This is generally considered to be a special case of dener-
vation hypersensitivity. Reduced circulating and vascular
concentrations of norepinephrine or epinephrine, or both,
may lead to the expression of increased numbers of beta-
receptors (30-33) or to the presence of increased numbers
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Figure 4. Response of a 72 year old man (Case 2) with the Brad-
bury-Eggleston syndrome to oral (P.O.) terbutaline. A substantial
decrease in blood pressure (BP) is evident, although its magnitude
is perhaps attenuated by the attendant tachycardia ("Treppe phe-
nomenon"). HR = heart rate.
of beta-receptors in an increased affinity state (34). It is
noteworthy that the beta-receptors that have received the
greatest attention in patients with autonomic dysfunction
have been those located on the membranes of white blood
cells, which appear functionally to be of the betaz class.
The vascular beta-receptor is also classified as belonging to
this subtype.
Isoproterenol testing. This has been used for a number
of years to assess the adequacy of beta-receptor blockade
in human studies (9,35,36). These studies have generally
utilized the heart rate response to indicate the level of beta
blockade. Although the decrease in blood pressure after
isoproterenol was noted even in the early studies (35), it
was not generally thought that this would interact with the
heart rate response to introduce an artifactual enhancement
of the direct chronotropic effect of the drug. However, the
maximal increase in heart rate in normal subjects tends to
occur a few seconds after the nadir of the depressor re-
sponse. Thus, it seems likely that the chronotropic effect
of isoproterenol in normal subjects results from both the
direct chronotropic effect of the drug and the hypotension-
induced reflex tachycardic response.
TIME (H)
Betaz versus beta} hypersensitivity. This latter consid-
eration may be very important in the apparent betaz hyper-
sensitivity in the Bradbury-Eggleston syndrome. These in-
dividuals have lost their reflex capacity to buffer their
cardiovascular system against the pressor and depressor stimuli
of daily life. Thus one would expect that, even if no alter-
ations in number or affinity of beta-receptors occurred, there
would still be an apparent enhancement of beta effect on
the vasculature because of the reduced capacity of patients
with autonomic dysfunction to buffer the depressor stimu-
lus. However, the loss of baroceptor function has another
important consequence. The contribution that the baroceptor
makes to the tachycardic response of isoproterenol in normal
subjects does not occur in the absence of this reflex. Hence,
this will add to the apparent disparity between the chron-
otropic beta l and vascular betaz sensitivity seen in these
patients. It is thus possible that the difference in betal hy-
persensitivity between Bradbury-Eggleston patients and nor-
mal subjects is underestimated by the assessment method
employed.
Clinical implications. Whatever the hemodynamic
mechanism underlying the differential responsiveness ob-
served, it seems clear that the observations have clinical
relevance. Ordinary doses of isoproterenol in patients with
autonomic dysfunction could lower blood pressure catas-
trophically. Even the modest dose of terbutaline employed
in the patient shown in Figure 4 had profound effects on
both blood pressure and heart rate. Such hemodynamic ef-
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fects might be especially dangerous in individuals with ath-
erosclerotic lesions in the coronary or cerebral vessels. The
responses observed in patients with the Bradbury-Eggleston
syndrome reported here are similar to those we have seen
in patients with the Shy-Drager syndrome, amyloidotic auto-
nomic dysfunction or diabetic autonomic dysfunction and
in a patient with cervical cord section. Thus, it seems likely
that the phenomenon is generalized in all individuals with
impairment in autonomic function, whatever the pathologic
process. It seems prudent to withhold pure beta-agonists in
such subjects in proportion to the severity of their neurologic
impairment.
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